Announcements Trials
Browse Landscape

Phase

Phase 2 75Phase 1 41Phase 3 32Phase 1/2 21Phase 4 5Phase NA 4Phase EARLY_PHASE1 3Phase 2/3 2

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Hormone Receptor Positive HER-2 Negative Breast Cancer 1Breast Neoplasms 1

Interventions

Capecitabine 17Paclitaxel 16Docetaxel 13Carboplatin 12Cyclophosphamide 11Gemcitabine 9Epirubicin 9Trastuzumab 8Letrozole 8Doxorubicin 7pertuzumab 5Cisplatin 5Vinorelbine 4130-nm albumin-bound paclitaxel 4exemestane 3Zoledronic Acid 3Tamoxifen 3Neoadjuvant Therapy 3Lapatinib 3Injections 3Drug Therapy 3Ado-Trastuzumab Emtansine 3AC protocol 3pyrotinib 2palbociclib 2camrelizumab 2apatinib 2Thiotepa 2Taxes 2Standard of Care 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × palbociclib × Breast × Clear all
NCT04191499 2026-03-17

INAVO120

Hoffmann-La Roche

Phase 2/3 Active not recruiting
325 enrolled 14 charts 1 FDA
Breast

Breast Neoplasms

NCT02692755 2021-09-28

PALINA

Georgetown University

Phase 2/3 Completed
35 enrolled 12 charts
Breast

Hormone Receptor Positive HER-2 Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡